Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
Smith+Nephew (NYSE:SNN) has signed an exclusive US distribution agreement with RMR Ortho to add the A’TOMIC™ Nitinol Fixation System to its Trauma, Foot & Ankle and Hand & Wrist portfolio. The system uses nitinol for active compression aiming to improve implant integrity and patient comfort. The partnership leverages Smith+Nephew’s US commercial scale to expand surgeon access and deepen engagement.
Smith+Nephew reported $5.8 billion in annual sales for 2024 and will distribute A’TOMIC across key US territories.
Smith+Nephew (SNN) signed a distribution agreement with SI-BONE to add the iFuse TORQ portfolio, expanding offerings for percutaneous pelvic fracture fixation and sacroiliac joint fusion. The iFuse TORQ TNT has FDA Breakthrough Device Designation and is NTAP-eligible, potentially adding up to $4,136 per procedure in reimbursement.
The deal grants Smith+Nephew access to SI-BONE’s sales channel and aims to deepen surgeon engagement in high-frequency trauma procedures.
Smith+Nephew (NYSE:SNN) has completed the acquisition of Integrity Orthopaedics, adding the Tendon Seam™ rotator cuff repair (RCR) system to its sports medicine shoulder portfolio.
Tendon Seam™ features patented microanchors, continuous suture and an integrated instrument, received 510(k) clearance in 2023, and is available in the US. Smith+Nephew positions Tendon Seam™ alongside its REGENETEN bioinductive implant to offer combined biomechanical and biological RCR solutions. The release cites ~500,000 annual US RCR procedures and historical re‑tear rates of 20–40%, while noting early clinical experience showing low re‑tear rates and shorter procedures.
Smith+Nephew (NYSE:SNN) published a comparative real-world analysis of single-use negative pressure wound therapy (sNPWT) using >22,000 patients from the Premier PINC AI healthcare database. The study reports that PICO sNPWT (-80 mmHg) produced materially better outcomes versus Prevena -125 mmHg in orthopedic (17,000+ patients) and cardiovascular (5,000+ patients) surgery.
Key quantified findings: 57.8% and 63.9% relative reductions in wound dehiscence risk, shorter hospital length of stay (cardio 6.33 vs 6.86 days; ortho 2.43 vs 3.10 days), and index/30–90 day admission cost reductions ranging ~13%–22% (all p-values reported).
Smith+Nephew (NYSE:SNN) and UFC announced a multi-year extension of their worldwide marketing partnership on October 22, 2025, with Smith+Nephew remaining UFC’s Preferred Sports Medicine Technology Partner.
The renewal continues branded activations at major UFC events, athlete integrations, and an education program: the second Smith+Nephew UFC Combat Sports Medicine Course will be held in Las Vegas from February 18-20, 2026. The partnership highlights Smith+Nephew sports medicine technologies, including the REGENETEN and CARTIHEAL AGILI-C implants, and cites athlete ambassadors who received treatment with the company’s technologies.
Smith+Nephew (NYSE:SNN) announced that the AMA CPT Editorial Panel has established a Category I CPT code for procedures using the CARTIHEAL AGILI-C cartilage repair implant, effective January 1, 2027. The implant is described as a single‑stage, off‑the‑shelf aragonite-based scaffold, commercially available in the United States including Puerto Rico.
The company notes CARTIHEAL has FDA Breakthrough Device designation and is the only FDA‑approved device for this indication. A multicenter randomized trial reported an 87% relative risk reduction in progression to total knee arthroplasty or osteotomy at 4 years versus microfracture/debridement. The new code is expected to streamline reimbursement and broaden clinical access.
Smith+Nephew (NYSE:SNN) announced peer‑reviewed data (Int Wound J, 2025) showing the new ALLEVYN COMPLETE CARE 5‑Layer Foam Dressing absorbs 93% of mechanical energy, dissipating shear and friction internally. Results used Frictional Energy Absorber Effectiveness (FEAE) and Finite Element Modelling (FEM) to confirm the dressing's mechanistic protection of soft tissue. FEAE improved from 30–45% (ALLEVYN LIFE) to 93%. The PR cites US annual pressure injury costs of $26.8bn. The product will launch in the US later in 2025, with roll‑out across other markets through 2026.
Smith+Nephew (NYSE:SNN) has launched its CORIOGRAPH Pre-Op Planning and Modeling Services for total shoulder arthroplasty in the United States, completing its CORIOGRAPH Services portfolio that includes knee and hip solutions.
The innovative software provides CT-based 3D planning capabilities with enhanced clinical decision-making through advanced biomechanical simulation. Key features include patient-specific anatomical modeling, impingement minimization, and range-of-motion simulation accounting for scapulothoracic motion. The system integrates seamlessly with Smith+Nephew's AETOS Shoulder System, designed to enhance surgical efficiency with fewer instruments and simplified conversion procedures.
The first procedures using CORIOGRAPH Services for Shoulder were successfully completed at Duke University, with Dr. Christopher Klifto highlighting the system's precision planning capabilities and unique Activity of Daily Living function for optimizing range of motion.
Smith+Nephew (NYSE:SNN) has announced significant updates for its REGENETEN Bioinductive Implant, a medical device for treating rotator cuff tears and soft tissue injuries. The American Academy of Orthopaedic Surgeons (AAOS) has issued a strong recommendation for bioinductive implants, highlighting their value in rotator cuff repair.
A key two-year randomized controlled trial demonstrated a 65% relative reduction in re-tear rates when using REGENETEN (12.3% vs 35.1% with standard repair). Additionally, Smith+Nephew has received approval to market the implant for extra-articular ligament injuries in the US, expanding its treatment potential beyond the current 150,000 procedures completed globally since 2014.
Smith+Nephew (NYSE:SNN) has launched the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel treatment for chronic wounds. The system, which uses a patient's own platelets and plasma, is designed for managing various wound types including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
The CENTRIO PRP System is supported by two randomized controlled clinical trials and has received CMS coverage for treating chronic non-healing wounds in diabetic patients. The system can be used in both hospital and physician office settings, with the gel being customizable to fit different wound characteristics using a single blood draw.
Smith+Nephew has entered into an exclusive private label distribution agreement with Nuo Therapeutics Inc. to market the system in the United States.